Amgen Inc.: timeline
Every dated event on file, newest first: history, results, dividends, splits, index changes, insider trades, layoffs and recalls, each with its source.
88 events
On the market-cap history; source: Market-cap history on value.today.
Point at a marker under the line to see the event. Green: good news by its nature (a raise, an index entry), orange: bad (a cut, a layoff), grey: neither.
2026
- Nov 3, 2026Results released
Form 8-K filed 03 Nov 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 4, 2026Results released
Form 8-K filed 04 Aug 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jul 29, 2026Cybersecurity incident
A cybersecurity incident the company judged material.
Notable 8-K events · source: SEC EDGAR (Form 8-K)
- Jun 4, 2026Recall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC
N/A
Product recalls · source: Drugs (FDA)
- Apr 30, 2026Results released
Form 8-K filed 30 Apr 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Feb 13, 2026Annual report filed (Form 10-K)
For the year to 31 Dec 2025
Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)
- Feb 3, 2026Results released
Form 8-K filed 03 Feb 2026
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2025
- Dec 31, 2025Dividend raised 5.9% to $2.52 a share
Quarter to 31 Dec 2025
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Nov 4, 2025Results released
Form 8-K filed 04 Nov 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 5, 2025Results released
Form 8-K filed 05 Aug 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- May 1, 2025Results released
Form 8-K filed 01 May 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Mar 31, 2025Dividend raised 5.8% to $2.38 a share
Quarter to 31 Mar 2025
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Feb 27, 2025Recall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use O
313,620 Vials
Product recalls · source: Drugs (FDA)
- Feb 14, 2025Annual report filed (Form 10-K)
For the year to 31 Dec 2024
Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)
- Feb 4, 2025Results released
Form 8-K filed 04 Feb 2025
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- 2025Record revenue of $36.8 billion
FY2025, the highest of the 19 years on record.
Company history · source: Financial years
2024
- Oct 30, 2024Results released
Form 8-K filed 30 Oct 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 6, 2024Results released
Form 8-K filed 06 Aug 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- May 2, 2024Results released
Form 8-K filed 02 May 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Mar 31, 2024Dividend raised 5.6% to $2.25 a share
Quarter to 31 Mar 2024
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Feb 14, 2024Annual report filed (Form 10-K)
For the year to 31 Dec 2023
Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)
- Feb 6, 2024Results released
Form 8-K filed 06 Feb 2024
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
2023
- Oct 31, 2023Results released
Form 8-K filed 31 Oct 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Oct 6, 2023Horizon Therapeutics Public Company became a subsidiary
From the Wikidata entry of Horizon Therapeutics Public Company.
Company history · source: Wikidata
- Oct 6, 2023Acquisition or sale completed
A significant acquisition or disposal of assets was completed.
Notable 8-K events · source: SEC EDGAR (Form 8-K)
- Aug 3, 2023Results released
Form 8-K filed 03 Aug 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jun 13, 2023
- Apr 27, 2023Results released
Form 8-K filed 27 Apr 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Mar 16, 2023
- Jan 30, 2023Results released
Form 8-K filed 31 Jan 2023
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jan 24, 2023
2022
- Dec 31, 2022Dividend raised 9.8% to $2.13 a share
Quarter to 31 Dec 2022
Dividend raises and cuts · source: SEC filings (dividends declared per share)
- Dec 25, 2022Entered the world's top 100 companies by market cap
Ranked #80 with $140.8 billion on 25 December 2022, up from #113 on 7 January 2022.
Company history · source: Market-cap rankings
- Nov 3, 2022Results released
Form 8-K filed 03 Nov 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Aug 4, 2022Results released
Form 8-K filed 04 Aug 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Jun 15, 2022
- May 2, 2022Recall: MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Ma
15,823
Product recalls · source: Drugs (FDA)
- Apr 27, 2022Results released
Form 8-K filed 27 Apr 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
- Feb 7, 2022Results released
Form 8-K filed 07 Feb 2022
Results releases · source: SEC EDGAR (Form 8-K, item 2.02)
Share price moves are worked out where the site has the listing's daily prices from the exchange itself: India (NSE), Taiwan (TWSE, TPEx), Brazil (B3), Poland (GPW), Russia (MOEX), Hong Kong (HKEX) and Sri Lanka (CSE). US listings have no daily price source on the site yet.